Статьи
ФАРМАТЕКА » Применение азитромицина для лечения внебольничных пневмоний у взрослых и детей
08.10.2017
Применение азитромицина для лечения внебольничных пневмоний у взрослых и детей
И.П. Фомина, Е.А. Ушкалова
В статье рассматриваются критерии и алгоритмы выбора антибиотиков при эмпирическом лечении внебольничной пневмонии, занимающей важное место в структуре заболеваемости и смертности экономически развитых стран. Обосновывается применение азитромицина при этом заболевании у взрослых пациентов и детей с учетом этиологии заболевания, уровня резистентности основных возбудителей к макролидам и данных об эффективности, безопасности и затратной эффективности препарата при внебольничной пневмонии.
Литература
Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia for adults. Clin Infect Dis 2000;31:347-82. Lave, JR, Lin CJ, Fine MJ, et al. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999;20:189-97. Stanton M. Improving Treatment Decisions for Patients with Community-Acquired Pneumonia. Research in Action, Issue 7. AHRQ Publication Number 02-0033, July 2002. http://www.ahrq.gov/clinic/pneumonia/pneumonria.htm. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. Инфекции нижних дыхательных путей. В книге: «Практическое руководство по антиинфекционной химиотерапии» (под редакцией Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова), М., 2002. - С. 219-225. Cosentini R, Tarsia P, Blasi F, et al. Community-acquired pneumonia: role of atypical organisms. Monaldi Arch Chest Dis 2001;56:527-34. Ноников В.Е. Пневмонии: антибактериальная терапия // В мире лекарств. – 1998. - № 1. Barlett JR, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect. Dis 1998;26:811-38. Комадина К.X., Джилл М., Киш М. Э. и др. Пневмонии внебольничного происхождения – амбулаторное лечение больных в возрасте 16 лет и старше // Международный медицинский журнал. – 2000. - № 6. Fine MJ, Auble ТЕ, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. Страчунский Л.С. Состояние антибиотикорезистентности в России // Клиническая фармакология и терапия. – 2000. - № 2. – C. 6-9. Zinner SH. Macrolides and streptogramins. In: Current Infectious Disease Drugs. Andriole VT (Ed.), 1-st ed. Philadelphia, 1995:139-147. Шабалов Н.П., Маркова И.В. Антибиотики и витамины в лечении новорожденных. Санкт-Петербург, АО "Сотис", ТОО "Технобалт", 1993. 255 c. Meyler’s side effects of drugs. 13-th ed. Ed. Dukes MNG. Elsevier Science, 1996:693-744. Dunn JC, Barradell LB. Azithromycin: a review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996;51:483–505. Matsunaga T. [Pharmacological and pharmacokinetic properties of azithromycin. (Zithromac), a novel 15-membered ring macrolide antibacterial agent] Nippon Yakurigaku Zasshi 2001;117:343-9. Girard AE, Cimochowski CR, Faiella JA. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. J Antimicrob Chemother 1996;37(suppl. C):9-19. Onodera S, Shiba K. Tissue and body fluid concentrations of azithromycin. In: The Third International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, Abstr. 4.14. Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001;61:443-98. Guay DRP. Macrolide antibiotics in paediatric infectious diseases. Drugs 1996;51:515-36. Ives TE, Regenery RL, Manzewitsch P, et al. In vitro evaluation of macrolide antibiotics against Bartonella henselae, B. Quintana and B. elizabetheae via immunofluorescent antibody testing. In: The Third International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, Abstr. 8.10. Steigbigel NH. Macrolides and clindamycin. In: Principles and Practice of Infectious Diseases. 4 th ed. Mandell GL, Bennett JE, Dolin R (Eds), New York, etc., 1995:334-346. Odenholt-Tornqvist I, Lowdin E, Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 1995;39:221-6. Ноников В.Е. Атипичные пневмонии: второе рождение макролидов // Новый медицинский журнал. – 1995. - № 1. – С. 5-7. Amsden GW, Nafziger AN, Foulds G. Abstr. of The 4-th Intern. Conference on the macrolides, azalides, streptogramins & ketoldes, Barselona, 1998: 109. Abstr. 12.05. Bohte R, van't Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995;14:182–7. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother 1993;31(suppl. E):153-62. Clement PA, de Gandt JB. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults. J Int Med Res 1998;26:66-75. Daniel RR. Comparison of azithromycin and coamoxiclav in the treatment of otitis media in children. J Antimicrob Chemother 1993;31(suppl. E):65-71. Felstead SJ, Daniel R. Short-course treatment of sinusitis and other upper respiratory tract infections with azithromycin: a comparison with erythromycin and amoxycillin. European Azithromycin Study Group. J Int Med Res 1991;19:363-72. Ficnar B, Huzjak N, Oreskovic K, et al. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group. J Chemother 1997;9:38-43. Galova K, Sufliarska S, Kukova Z, et al. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in163 children: azithromycin versus ceftibuten. Chemotherapy 1996;42:231-4. Pavic-Sladoljev D, Oreskovic [Patient compliance in the treatment of respiratory tract infections] K Lijec Vjesn 1997;119:193-200. Favre O, Delacretaz E, Badan M, et al. Relationship between the prescriber's instructions and compliance with antibiotherapy in outpatients treated for an acute infectious disease. J Clin Pharmacol 1997;37:175-8. Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Pediatr Infect Dis J 1996;15(suppl. 9):S30-7. Steele RW, Estrada B, Begue RE, et al. A double-blind taste comparison of pediatric antibiotic suspensions. Clin Pediatr (Phila) 1997;36:193-9. Medina AJ, Jerez BB, Brusint OB, et al. Azithromycin compared with erythromycin as initial therapy for community-acquired pneumonia. In: The 33rd International Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1993: abstr.5239. Contopoulos-Ioannidis, DG, Ioannidis JP, Chew P, Lau JJ. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001;48:691-703. Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 1999;11:107-18. Kuzman I, Schonwald S, Culig J. Azithromycin in the treatment of community-acquired legionnairs’ disease. In: The Third International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996, Abstr. 1.05. Langtry HD, Balfour JA. Azithromycin. A review of its use in paediatric infectious diseases. Drugs 1998;56:273-97. Ferwerda A, Moll HA, Hop WC, et al. Antimicrob Chemother 2001;47:441-6. Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996;37(suppl. C):143–9. Hopkins S. Clinical safety and tolerance of azithromycin in children. Journal of Antimicrobial Chemotherapy 1993;31(suppl. E):111-7. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf 1999;20:25–41. Langtry HD, Balfour JA. Azithromycin. A review of its use in paediatric infectious diseases. Drugs 1998;56:273-97. Treadway G, Reisman A. Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases. Int J Antimicrob Agents 2001;18:427-31. Treadway G, Pontani D, Reisman A. The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections. Int J Antimicrob Agents 2002;19:189-94. Ioannidis JPA, Contopoulos-Ioannidis DG, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tractinfections. J Antimicrob Chemother 2001;48:677-89. Jacobs RF, Schutze GE, Yong RA. In: Principles and practice of pediatric infectious diseases. Ed: Long SS, Pickering LK, Rober CG. NY, 1997:1604-62. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001;18(suppl. 1):S71-6. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002;62:1481-502. Карпов О.И. Комплаенс антибиотикотерапии инфекций дыхательных путей // Антибиотики и химиотерапия. – 1999. – Т. 44. – № 8. – С. 37-45.